Navigation Links
Amylin Pharmaceuticals to Present at Goldman Sachs 32nd Annual Global Healthcare Conference and Jefferies Global Life Sciences Conference
Date:5/31/2011

SAN DIEGO, May 31, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Goldman Sachs 32nd Annual Global Healthcare Conference on Tuesday, June 7, 2011, at 12:20 p.m. ET / 9:20 a.m. PT in Palos Verdes, California and at the Jeffries Global Life Sciences Conference on Wednesday, June 8, 2011, at 10:00 a.m. ET / 7:00 a.m. PT in New York.  Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview at the Goldman Sachs conference.  Mark Foletta, senior vice president, finance and chief financial officer of Amylin, will provide a corporate overview at the Jeffries conference.

The presentations will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and the recordings will be made available on the website following the events. To access the live webcasts, please log on to Amylin's website approximately fifteen minutes prior to the presentations to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin to Advance Key Value-Driving Opportunities in 2011
2. Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin
3. Amylin Pharmaceuticals to Present at the Citi 7th Annual US Small/Mid Cap Conference
4. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
5. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
6. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
7. Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference
8. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
9. Amylin Pharmaceuticals to Webcast Third Quarter Results
10. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
11. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Haven, Connecticut (PRWEB) , ... May 25, 2016 ... ... that the U.S. Food and Drug Administration (FDA) has granted the company’s orphan ... is the company’s second orphan drug designation granted by the FDA. , ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... re-branded identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization for ... and image analysis. The re-branding components include a crisp, refreshed logo and a ...
(Date:5/23/2016)... Oxitec CEO Hadyn Parry ... a.m. ET before the United States House Committee on Science, ... play in controlling the spread of the Aedes aegypti ...      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) Oxitec ... gene. Trials in Brazil , ...
(Date:5/22/2016)... ... , ... Doctors in Rome say micronutrients found in certain foods have the ... has just posted an article on the new research. Click here to read ... and Translational Medicine evaluated more than 150 studies on polyphenols in cancer for their ...
Breaking Biology Technology:
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):